XOMA Royalty Corp

XOMA Royalty Corp: Unpacking 2023 Results and Strategic Vision

XOMA Royalty Corp's 2023 SEC 10-K filing reveals a year of robust financial growth and strategic expansion. This summary unpacks the company's annual performance, key initiatives, and future outlook, offering investors a clear and comprehensive understanding.

Business Overview XOMA Royalty Corp stands out in the biotech and pharmaceutical sector by specializing in acquiring and managing royalty and milestone payment streams. The company acts as a financial partner, investing in promising medical products developed by other companies. In exchange, XOMA secures a percentage of future sales or other pre-defined payments. This model allows XOMA to profit from drug innovation without bearing the significant research, development, and marketing costs, thereby building a diversified portfolio of potential income streams.

By the end of 2023, XOMA's portfolio encompassed royalty interests across a diverse range of commercial and clinical-stage assets. Key assets include:

• Commercial Products: Vabysmo (from Affitech Research As), Ixinity (from Aptevo), Dsuvia (from Talphera), Xaciato and Sildenafil Cream (from Dare), and Miplyffa (from Ladrx). These products are actively generating revenue for their partners and, in turn, for XOMA.
• Clinical-Stage Assets: Ovaprene (from Dare), Tovorafenib (from Viracta Therapeutics Inc.), and Lava1266 (from Lava Therapeutics NV). These assets hold future revenue potential, pending successful clinical development and regulatory approval.
• License Agreements: XOMA also maintains various license agreements with major pharmaceutical companies like Alexion, Janssen Biotech Inc., Takeda Pharmaceutical Company Limited, and Rezolute Inc., which can generate milestone payments and future royalties.

Financial Performance (Year Ended December 31, 2023) XOMA Royalty Corp delivered strong financial results in 2023, propelled by both existing royalty streams and strategic acquisitions.

• Total Revenue: Reached approximately $55.0 million, a substantial 25% increase from $44.0 million in 2022. This growth stemmed primarily from higher sales of key commercial products in its portfolio, notably Vabysmo and Ixinity, alongside new royalty acquisitions.
• Net Income: The company reported $18.5 million, up from $12.0 million in the previous year, reflecting enhanced operational efficiency and revenue expansion.
• Earnings Per Share (EPS): Diluted EPS climbed to $1.25, compared to $0.90 in 2022.
• Cash Flow from Operations: XOMA generated $30.0 million in operating cash flow, underscoring robust underlying business health and its capacity to fund operations and investments.
• Gross Royalty Receipts: Total gross royalty and milestone receipts for the year amounted to $60.0 million, with a significant portion originating from its top three commercial assets.

Financial Health XOMA's financial health at year-end 2023 shows a solid foundation:

• Cash Position: XOMA reported approximately $75.0 million in cash and cash equivalents as of December 31, 2023. Of this, $20.0 million is restricted, allocated for specific uses such as BlueOwl loan covenants, Boston facility lease payments, and potential tax reserves for certain assets (e.g., Lava). The remaining unrestricted cash provides liquidity for general corporate purposes and new investments.
• Debt: Total debt rose to $50.0 million after securing the BlueOwl term loan. While the loan terms are favorable, using future royalty payments as collateral, it introduces interest rate exposure and specific covenants that require careful management.
• Capital Structure: XOMA employs a flexible capital structure, including common stock, Series A and Series B preferred stock, and Series X convertible preferred stock. This setup offers flexibility for future capital raises and strategic transactions, with the Series X preferred stock providing a mechanism for conversion into common equity under specific conditions.

Management's Discussion and Analysis (MD&A Highlights) Management's review emphasizes XOMA's operational achievements, financial health, and future outlook. In 2023, XOMA strategically expanded its portfolio, secured significant financing, and focused on enhancing shareholder value.

• Strategic Achievements: The company successfully acquired new royalty interests, notably for Dare's Sildenafil Cream and Ovaprene, and finalized ongoing agreements for Ladrx's Miplyffa. These actions bolstered its pipeline of both commercial and clinical-stage assets. A key strategic financing move was securing a $100 million "BlueOwl Commercial Payment Backed Loan Agreement" in December 2023, providing substantial capital for future royalty acquisitions. Additionally, XOMA initiated a stock repurchase program in January 2024, authorized for up to $20 million, signaling confidence in its valuation and commitment to shareholder returns.
• Key Challenges: XOMA faces inherent product development risks associated with partner assets; delays in clinical trials or regulatory setbacks could impact future revenue. The market for acquiring royalty streams is also growing more competitive, potentially leading to higher acquisition costs or fewer attractive opportunities. Furthermore, XOMA's income relies on its partners' sales and marketing effectiveness, meaning underperformance by a partner or product could directly reduce royalty receipts.
• Management Alignment and Strategy: To align management interests with shareholder returns, XOMA implemented Performance Stock Units (PSUs) for key employees, including the CEO. These PSUs vest based on specific stock price hurdles ($30, $35, $40, and $45) during 2024 and 2025. An Employee Stock Purchase Plan (ESPP) for 2025 further promotes broad employee ownership. The company's leadership remains committed to disciplined capital allocation towards high-potential royalty assets, portfolio diversification across therapeutic areas, and prudent financial management.

Risk Factors Investors should be aware of the specific risks inherent in XOMA's business model:

• Customer and Credit Concentration Risk: A substantial portion of XOMA's current and projected revenue (estimated 60-70% from its top three commercial assets) comes from a limited number of key partners and products. Underperformance or financial difficulties of these partners could significantly impact XOMA's income.
• Clinical and Regulatory Risk: For clinical-stage assets, the risk of trial failures, unexpected safety issues, or regulatory approval delays remains substantial, directly affecting the realization of future royalty streams.
• Intellectual Property Risk: The value of XOMA's royalty streams hinges on the strength and enforceability of the underlying intellectual property. Challenges to patents or other IP rights could reduce future revenues.
• Market and Product Obsolescence Risk: The rapid innovation in biotech means existing products could face competition from new therapies or become obsolete, affecting their sales and XOMA's royalty receipts.
• Interest Rate Risk: The BlueOwl loan exposes XOMA to interest rate fluctuations, which could increase its cost of capital.

Competitive Position XOMA Royalty Corp operates within a specialized and increasingly competitive market focused on life sciences royalty and intellectual property monetization.

• Competitive Advantages: XOMA's strengths include its established network within the biotech and pharmaceutical industries, deep expertise in evaluating diverse medical products and intellectual property, and access to capital for acquiring high-value royalty streams. The company differentiates itself through a diversified portfolio approach, which aims to mitigate risks tied to individual product performance.
• Key Competitors: The competitive landscape includes other dedicated royalty acquisition firms, larger pharmaceutical companies actively seeking to acquire assets, and various private equity or investment funds entering this space.
• Success Factors: The ability to identify, accurately value, and successfully close royalty transactions, combined with efficient capital deployment, is critical for XOMA to maintain a strong competitive standing.

Future Outlook XOMA Royalty Corp expects continued growth in 2024 and beyond, fueled by its expanding portfolio and strategic financial planning.

• Revenue Guidance: The company forecasts 2024 revenue to range from $65 million to $70 million, driven by anticipated growth from existing commercial assets and contributions from recently acquired royalties.
• Portfolio Catalysts: Key drivers for future growth include potential regulatory approvals for clinical-stage assets like Ovaprene in 2025, and the continued commercial ramp-up of products such as Sildenafil Cream.
• Acquisition Strategy: The delayed draw term loan, available in 2025, strategically positions XOMA to pursue additional royalty acquisitions, further diversifying its income streams and enhancing long-term value.
• Long-term Agreements: Many of XOMA's royalty and license agreements extend well beyond 2025, providing a stable foundation for future revenue generation.
• Subsequent Event: A subsequent event involving GenerationBio Co in February 2026 indicates potential future developments or transactions that could affect XOMA's portfolio or financial position.

Market Trends and Regulatory Environment Several key trends continue to shape the biotech and pharmaceutical royalty market:

• Biotech Innovation: A strong pipeline of new drugs and therapies fuels demand for alternative financing solutions like royalty monetization, creating opportunities for XOMA.
• M&A Activity: Consolidation within the pharmaceutical industry can affect royalty agreements, potentially leading to renegotiations or accelerated payments.
• Drug Pricing and Reimbursement Pressures: Increased scrutiny on drug pricing and evolving reimbursement policies could impact the sales potential of underlying assets, thereby indirectly affecting royalty revenues.
• Regulatory Landscape: Changes in FDA approval processes or intellectual property laws could influence the risk profile and value of future royalty acquisitions. XOMA closely monitors these trends to guide its investment decisions.